🇺🇸 FDA
Patent

US 8075921

Rapamycin-resistant T cells and therapeutic uses thereof

granted A61KA61K2035/122A61K2035/124

Quick answer

US patent 8075921 (Rapamycin-resistant T cells and therapeutic uses thereof) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Dec 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Dec 13 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K2035/122, A61K2035/124, A61K2039/57, A61K2239/31